Effect of Milnacipran in Patients With Fibromyalgia

Fibromyalgia patients will show elevated ventricular lactate levels as measured via magnetic
resonance spectroscopy (MRS). Patients treated with Milnacipran will show normalization of
ventricular lactate levels compared to those treated with placebo, and will also show
normalization of the increased latency to respond to complex reaction time probes compared
to those treated with placebo.

Inclusion Criteria:

- Female or male subjects who fulfill the American College of Rheumatology's case
definition for Fibromyalgia.

- 18 through 60 years of age

Exclusion Criteria:

- Pregnant or trying to become pregnant

- Taking any other SNRI or already taking milnacipran

- Patients who do not indicate their pain levels as less than substantial despite
their best care

- History of any psychotic disorder or history of alcoholism or drug abuse within 10
years of intake as determined by psychiatric diagnostic interview

- Presence of current depression as determined by psychiatric diagnostic interview

- Presence of brain lesion on MRI anatomical study